Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Meridian Bioscience Receives FDA Clearance For New Rapid Campylobacter Test
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United States. Approximately 20 million stool culture tests are conducted each year in the U.S. to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact.
generic viagra online
Younger Men With Advanced Prostate Cancer Have Shorter Survival Times
While young men with prostate cancer have a low risk of dying early, those with advanced forms of cancer do not live as long as older men with similar forms of the disease. That is the conclusion of a new study published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The paradoxical findings indicate that there may be biological differences between prostate cancers that develop in younger men and those that develop in older men, and that uncovering these differences may help tailor screening and treatment strategies for patients based on age.
News of the day
Hospital Disaster Potential Highighted By Swedish Study
Factors that lead to emergency department overcrowdings, ambulance diversions and other incidents that endanger patient safety have been revealed. A study published in BioMed Central"s open access Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine has shown that reductions in the number of hospital beds and downsizing or closure of emergency departments may create a dangerous loss of "surge capacity".
Endocrinology

Labopharm Receives Complete Response Letter From The U.S. FDA For Novel Antidepressant

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for the new drug application (NDA) submission of its novel formulation of the antidepressant trazodone. The letter indicates Labopharm"s application cannot be approved in its present form due to deficiencies following an FDA inspection of the active pharmaceutical ingredient (API) manufacturing facility, which was completed July 3, 2009. The FDA letter states: "Satisfactory resolution of these deficiencies is required before this application may be approved." No efficacy or safety issues were raised. The API manufacturer, Angelini, has informed Labopharm that, further to the FDA"s complete response letter to Labopharm, in which the FDA raises observations concerning the Drug Master File (DMF) holder in the section "Facility Inspections", Angelini can confirm that the observations raised by the FDA are not critical and that it has not been questioned about the continued supply of trazodone hydrochloride to the U.S. market. Angelini intends to address the observations raised by the FDA in an action plan that Angelini is going to submit to the FDA by July 24, 2009. "We intend to work closely with the FDA and Angelini to resolve these issues as rapidly as possible," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We continue to prepare for the commercialization of our novel antidepressant and intend to launch in the U.S. market as soon as possible after we receive approval." The Company will provide further information regarding the timing of its response to the FDA when available. Labopharm submitted the NDA for its novel formulation of trazodone in September 2008. The NDA is based on data from five pivotal pharmacokinetic studies and the positive results from its North American Phase III placebo-controlled clinical trial (study 04ACL3-001), which enrolled more than 400 patients. About Labopharm Inc. Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company"s lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company"s second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm"s vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. This press release contains forward-looking statements, which reflect the Company"s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company"s products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company"s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements. Labopharm Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009